Medlab Clinical Ltd. in collaboration with Prof. Daniela Traini's team from Macquarie University and Woolcock Institute of Medical Research and Prof. Pall Thordarson's team from UNSW Sydney's RNA Institute, is excited to announce that the Nasal RNA program is entering the final phase of development. Funded by a NSW Govt. grant and as part of the Government's future antiviral/vaccine response, the program brought together three teams to determine the viability of a concept product: a nanoparticle RNA delivered nasally, featuring Medlab's patent protected NanoCelle®.

The earlier stages of this project have been completed, which were to perform feasibility studies using insulin. Insulin was chosen due to being a water-soluble biological molecule, traits shared with RNA, and which differentiate it from the small lipophilic molecules that have been the main subject of NanoCelle® technology. The collaboration succeeded in: encapsulating insulin with NanoCelle® technology, demonstrating that NanoCelle® encapsulated biological molecules were suitable for nasal delivery and moving nasal spray delivered insulin one step closer along the translational pathway to commercialization.

The final phase of the program (per the grant agreement) is around the RNA encapsulation in NanoCelle® and this will commence at Medlab's laboratories in UNSW Sydney. This final step requires various approvals before the encapsulation process can start. Subject to approvals for final phase commencement, optimistically a viability determination is likely before Christmas.